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sicians in 8 European countries. 171 specialists completed patient record forms 
(PRFs) on 969 individuals diagnosed with PV including details of diagnosis, con-
comitant conditions, symptoms, laboratory values and treatment history. Data for 
patients currently receiving HU therapy for more than 3 months were compared 
with 4 elements of the ELN consensus paper (need for phlebotomy, uncontrolled 
myeloproliferation, failure to reduce massive splenomegaly and presence of leg 
ulcers). Results: 499 of the 969 patients (51%) were currently receiving HU for a 
period of more than 3 months. They had a mean age of 68.5 years and had been 
diagnosed for an average of 39.1 months; 58% were male. Based on the ELN con-
sensus criteria published by the British Journal of Haematology (Barosi et al, 2009), 
200 (40%) of those currently receiving HU are classified as resistant/intolerant to 
HU-therapy. 139 patients (70%) were receiving phlebotomy on average 3.4 times in 
the past 6 months, 61 (31%) had uncontrolled myeloproliferation (platelet count 
greater than 400x 109/L and white blood cell count greater than 10x 109/L), 5 (3%) 
had ulcers and 1 (1%) had massive splenomegaly. 102 (51%) physicians reported that 
they are not completely satisfied with HU treatment, with inadequate response 
the main cause of dissatisfaction. ConClusions: This analysis indicates that a 
proportion of patients continue to receive HU therapy despite being classified as 
resistant/intolerant according to the ELN consensus paper and a lack of satisfaction 
amongst physicians. The data support the need for more drug options in later lines 
of therapy, for patients resistant/intolerant to HU therapy.
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objeCtives: EGFR mutation-positive NSCLC represents a distinct subtype of NSCLC 
and its first-line treatment generally comprises erlotinib, gefitinib or afatinib. These 
agents have all shown progression-free survival improvement vs platinum-doublet 
chemotherapy (CT). However, a recent pair-wise meta-analysis of phase III clini-
cal trials based on individual patient-level data (n= 1231) demonstrated that the 
reversible EGFR TKIs, erlotinib and gefitinib, do not prolong overall survival (OS) vs 
CT, neither for the overall patient population nor for the individual mutation sub-
types, exon 19 deletions (Del19) and L858R.1 Here, we present a broader pair-wise 
meta-analysis including studies of the irreversible ErbB family blocker afatinib vs 
CT, as well as studies of erlotinib and gefitinib. Methods: Patients with common 
EGFR mutations (Del19 or L858R) treated with either afatinib (LUX-Lung 3, LUX-Lung 
6), erlotinib (ENSURE, EURTAC, OPTIMAL) or gefitinib (IPASS, NEJ002, WJTOG3405) 
in phase III clinical trials vs CT were included. Pooled treatment estimates using 
the inverse variance weighted method were calculated for all TKI vs CT compari-
sons in patients with Del19 or L858R. Results: In total, data from 1037 patients 
with Del19 and 816 patients with L858R mutations were analyzed. Afatinib sig-
nificantly improved OS vs CT in patients with Del19 (HR [95% CI]: 0.59 [0.45‒0.77]). 
For patients with Del19 there was no significant difference in OS, compared with 
CT, for either erlotinib (HR [95% CI]: 1.03 [0.77‒1.38]) or gefitinib (HR [95% CI]: 0.90 
[0.70‒1.17]). None of the agents improved OS vs CT in patients with L858R muta-
tions (afatinib: HR [95% CI] 1.25 [0.91‒1.71]; erlotinib: 0.98 [0.72‒1.35]; gefitinib: 1.11 
[0.81‒1.54]). ConClusions: No differences in OS were observed in the overall EGFR 
mutation-positive or the L858R population for afatinib, erlotinib, or gefitinib. In con-
trast to other TKIs, afatinib showed a significant OS benefit vs CT in Del19 patients. 
1Lee C, et al. J Clin Oncol 2015;33(suppl):abstract 8072
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objeCtives: To compare the efficacy of available treatments in patients with previ-
ously treated advanced/metastatic non-small cell lung cancer (NSCLC) Methods: 
Clinical trials of ceritinib, crizotinib, pemetrexed, docetaxel, erlotinib, and best sup-
portive care (BSC) in previously treated, crizotinib-naïve NSCLC were identified in 
a systematic literature review (up to March 2014). Since only single-arm trials were 
available for ceritinib, a matching-adjusted indirect comparison between ceritinib 
trials and similarly-designed crizotinib trials was used to link ceritinib into the 
evidence network. A Bayesian-based network meta-analysis (NMA) was then con-
ducted to compare overall survival (OS), progression-free survival (PFS) and overall 
response rate (ORR) among the studied treatments. Relative treatment effects and 
corresponding 95% credible intervals (CrIs) were estimated as well as the posterior 
efficacy rankings. Results: Fourteen clinical trials, including two ceritinib single-arm 
trials (ASCEND-1 [NCT01283516], ASCEND-3 [NCT01685138]), were included. Sample 
sizes ranged from 49 to 488 patients per arm. Ceritinib was associated with signifi-
cantly prolonged OS compared to crizotinib (hazard ratio [HR]: 0.58; 95%CrI: 0.41-0.83), 
pemetrexed (0.44; 0.26-0.76), docetaxel (0.47; 0.28-0.82), erlotinib (0.44; 0.26-0.80), and 
BSC (0.29; 0.16-0.55). Ceritinib also showed improved PFS compared to crizotinib (0.45; 
0.18-1.56), pemetrexed (0.18; 0.06-0.83), docetaxel (0.17; 0.06-0.84), erlotinib (0.15; 0.05-
0.90), and BSC (0.08; 0.02-0.69). Ceritinib increased the odds of achieving ORR by 38% 
compared to crizotinib, and was associated with ≥ 3 times higher ORR compared 
to other treatments. Ceritinib was the most efficacious treatment in terms of OS 
(posterior probability 99%), PFS (92%) and ORR (63%) among all treatments, followed 
pany. Results: Publicly-available guidance on RWE data collection by HTA and 
reimbursement authorities is almost entirely lacking, with the exception of The 
Netherlands, where there is a well-established process for post-launch data col-
lection. Published data sources were limited to two studies, both with a focus on 
safety. Market access specialists highlighted five categories of RWE data types. All 
countries expressed a requirement for patient characteristics, treatment patterns 
and effectiveness. Resource use and quality of life were considered supportive 
but not essential. A current or planned melanoma registry was identified in most 
countries, but the range of data collected and national coverage varied substan-
tially. ConClusions: There is very little formal guidance on RWE requirements in 
Europe, and no consistency across countries. In some cases (France, Germany, The 
Netherlands), there is an established infrastructure, although there is substantial 
variation between countries. Market access specialists anticipate increasing require-
ments for RWE in coming years but, currently, such data can be considered sup-
portive rather than essential. Therefore, manufacturers with new or development 
drugs must anticipate future, expanding requirements for RWE in their post-launch 
data generation programmes.
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objeCtives: To determine country-specific requirements for real-world evidence 
(RWE) in Europe to support ongoing market access for new drugs to treat non-
small cell lung cancer (NSCLC). Several new classes of drugs for NSCLC are coming 
to market and there is likely to be much competition. RWE is expected to play an 
important part in differentiating the new products and their most suitable target 
patient populations. Methods: We reviewed published health technology assess-
ments (HTAs) and reimbursement agency web sites to determine data sources for, 
or guidance on, RWE in France, Germany, Italy, The Netherlands, Spain, Sweden and 
the UK. In addition, we performed a pragmatic review of peer-reviewed literature 
to identify types of NSCLC RWE being published, and collected the views of market 
access specialists on RWE requirements among country representatives of a global 
pharmaceutical company. Results: Publicly-available guidance on NSCLC RWE 
data collection by HTA and reimbursement authorities is currently lacking. Likewise, 
data sources are highly limited in number and scope and there were no publications 
featuring feasible registries. Market access specialists highlighted five categories of 
RWE data types. All countries expressed a requirement for patient characteristics, 
treatment patterns and effectiveness. Resource use and quality of life were con-
sidered supportive but not essential. No current registries are able to meet these 
requirements. ConClusions: Formal guidance on RWE requirements in NSCLC in 
Europe is lacking and there is a need for registries to capture the range of data types 
highlighted by market access specialists to obtain and maintain market access. 
Given the level of development in the NSCLC field, and the number of likely new 
market entrants, manufacturers with new or developmental drugs need to help 
establish an infrastructure for collecting NSCLC RWE in Europe.
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objeCtives: Polycythemia Vera (PV) is associated with an overproduction of blood 
cells which leads to increased risk of blood clots and associated cardiovascular (CV) 
complications and may result in increased morbidity and mortality. This analy-
sis seeks to evaluate the impact of Hydroxyurea (HU) treatment on symptoms, 
concomitant conditions and cardiac risk. Methods: Data was drawn from the 
Adelphi PV Disease Specific Programme, a cross sectional survey of physicians in 
8 European countries. 171 specialists completed patient record forms (PRFs) on 
969 individuals diagnosed with PV including details of concomitant conditions, 
symptoms, treatment history, cardiac and/or thrombosis risk status and control 
status (both defined by the physician). Each physician completed a PRF for the last 6 
consulting patients. Results: 499 patients currently receiving HU treatment, for at 
least 3 months post diagnosis, were included in the analysis. At diagnosis 348 (70%) 
patients presented as symptomatic, 174 (35%) experienced headaches, 168 (34%) 
fatigue/weakness/tiredness and 166 (33%) pruritus/itching. 328 (66%) had concomi-
tant conditions, principally hypertension 204 (41%) and hyperlipidaemia 106 (21%). 
277 (56%) patients presented with splenomegaly with 99 (20%) reporting this as mod-
erate/massive. Cardiac events and/or thrombosis risk was reported as high in 283 
(57%) patients. Despite current use of HU, 216 (43%) patients are reported as being 
symptomatic, 110 (22%) due to fatigue/weakness/tiredness, 44 (9%) pruritus/itching 
and 34 (7%) headache. 306 (61%) experience concomitant conditions with hyperten-
sion remaining a problem for 186 (37%) patients. 51 (10%) patients report moderate/
massive splenomegaly whilst CV risk remains high for 156 (31%) of patients. 86 (17%) 
patients are not currently considered to be controlled. ConClusions: These find-
ings indicate that HU fails to adequately reduce cardiac risk in a proportion of PV 
patients. Despite treatment almost 1/5 (17%) patients were not considered to be con-
trolled and 2/5 (43%) reported symptoms; hence need exists for better treatments.
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objeCtives: Assess the level of resistance/intolerance to Hydroxyurea (HU) therapy 
in Polycythemia Vera (PV) patients in the real world setting across Europe, based on 
the European Leukemia Net (ELN) consensus paper. Methods: Data was drawn 
from the Adelphi PV Disease Specific Programme, a cross-sectional survey of phy-
